In the after-hours trading session, at the last check, TYME stock had surged by 6.98% to $1.38. TYME stock closed the previous session at $1.29. The TYME stock volume traded 2.44 million shares. In the past year up to date, TYME shares have plunged by -24.12% however in the past week they moved by 10.26%. In the past three and six months, the stock has shed -46.03% and added 36.23%. Furthermore, Tyme Technologies is currently valued in the market at $203.78 million and has 130.17 million outstanding shares.
What you need to know about Tyme Technologies Inc
Tyme Technologies, Inc. is a clinical-stage biotechnology company that centers on the creation on innovative therapeutics and treatments that are there to fulfill the unmet needs of patients. The organization was initially known as Global Group Enterprises Corp. Tyme Technologies, Inc. was established in 2011 and is settled in New York.
The company specifically focuses on cancer metabolism-based therapies (CMBTs). TYME has set up its operations in the United States. Its lead investigative up-and-comer is the SM-88 is a cancer metabolism-based therapy that is in Phase II/III clinical preliminary trial to treat a broad range of diseases which total at 15, including, sarcoma lymphoma, pancreatic, lung, prostate, and bosom; that are planned to be extensively viable across tumor types and have low harmfulness profiles. The Company’s remedial methodology is uniquely intended to exploit a malignant growth cell’s inborn metabolic shortcomings to bargain its protections, prompting cell passing through oxidative pressure and openness to the body’s normal insusceptible framework. With the improvement of TYME-18 and TYME-19, the Company accepts that it is likewise arising as an innovator in the advancement of bile acids as possible treatments for disease and infections, for example, COVID-19.
The organization likewise offers TYME-18, which is also a cancer metabolism-based therapy compound that is in the preclinical stage for the treatment of strong tumors. Tyme Technologies, Inc. has an investigation collaborated effort with NYU Langone Health to propel the improvement of therapies for patients with metastatic malignancies, including pancreatic disease, just as with Mayo Clinic; and essential cooperation with Eagle Pharmaceuticals, Inc. to propel oral SM-88 for the therapy of patients with the disease.
What is the recent update in the company?
On 13th May 2021, TYME stock declared that it has named Frank L. Porfido as its Chief Financial Officer, compelling not long after the Company records its yearly report on Form 10-K. Forthcoming has set up a chief with more than 25 years of vital monetary authority experience across little to huge size clinical and business stage Pharma organizations. Mr. Porfido is a Certified Public Accountant and did his BBA while specializing in Accounting-CPA Prep from Pace University, with his MBA done from Farleigh Dickinson University in Finance.
What does the company aim to do after hiring Frank as CFO?
CFO is a significant achievement for the Company as it is tirelessly attempting to finish the essential survey of the pipeline advancement programs. Up-and-comers like straightforward have administration and mastery that will be a priceless segment as the Company positions itself to push ahead and execute on the methodologies ahead. The organization hopes to be to giving more updates as it rollouts the outcomes from its essential audit in June.
TYME is ready for a groundbreaking year. The Company accepts there is enormous potential for the Company ahead and will require the aptitude of Frank for creating and carrying out essential field-tested strategies that he has accumulated throughout the span of his vocation will advantageously give the fundamental understanding as TYME progresses its endeavors.